SIGLEC-5,SIGLEC-14 Antikörper (FITC)
(2 Referenzen)-
- Target
- SIGLEC-5,SIGLEC-14
- Reaktivität
- Human, Schimpanse
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- FITC
-
Applikation
- Flow Cytometry (FACS)
- Kreuzreaktivität
- Schimpanse
- Produktmerkmale
- Purified IgG conjugated to Fluorescein Isothiocyanate Isomer 1 (FITC)
- Immunogen
- Siglec-5-Fc protein, consisting of the full-length extracellular region of human Siglec-5, fused with the Fc region of human IgG1.
- Klon
- 1A5
- Isotyp
- IgG1
-
anti-SIGLEC-5,SIGLEC-14 (Internal Region) antibody
Reaktivität: Human ELISA, IHC (p), WB Wirt: Kaninchen Polyclonal unconjugated
anti-SIGLEC-5,SIGLEC-14 antibody (PE)Reaktivität: Human, Schimpanse FACS Wirt: Maus Monoclonal 1A5 PE
anti-SIGLEC-5,SIGLEC-14 (Internal Region) antibodyReaktivität: Human ELISA, IHC (p), WB Wirt: Kaninchen Polyclonal unconjugated
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 0.1 mg/mL
-
-
: "Loss of Siglec expression on T lymphocytes during human evolution." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, Issue 20, pp. 7765-70, (2006) (PubMed).
: "Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation." in: The Journal of biological chemistry, Vol. 280, Issue 20, pp. 19843-51, (2005) (PubMed).
-
: "Loss of Siglec expression on T lymphocytes during human evolution." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, Issue 20, pp. 7765-70, (2006) (PubMed).
-
-
